SRR934795
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.329829172141919
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.432
- MITOTIC_SPINDLE+0.386
- ANDROGEN_RESPONSE+0.376
- TGF_BETA_SIGNALING+0.362
- E2F_TARGETS+0.346
- NOTCH_SIGNALING+0.338
- G2M_CHECKPOINT+0.325
- INTERFERON_ALPHA_RESPONSE+0.321
- MYC_TARGETS_V1+0.275
- UNFOLDED_PROTEIN_RESPONSE+0.240
Top 10 suppressed
- KRAS_SIGNALING_DN-0.364
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.255
- MYOGENESIS-0.234
- APICAL_SURFACE-0.227
- ANGIOGENESIS-0.222
- SPERMATOGENESIS-0.192
- APICAL_JUNCTION-0.185
- COAGULATION-0.174
- PANCREAS_BETA_CELLS-0.160
- ESTROGEN_RESPONSE_LATE-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934762 | — | — | 0.904 |
| 2 | SRR934754 | — | — | 0.904 |
| 3 | SRR934819 | — | — | 0.882 |
| 4 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.871 |
| 5 | SRR934788 | — | — | 0.867 |
| 6 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.866 |
| 7 | SRR934756 | — | — | 0.863 |
| 8 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.858 |
| 9 | SRR934783 | — | — | 0.852 |
| 10 | SRR934764 | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.432 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.386 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.376 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.362 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.346 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.338 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.325 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.321 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.275 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.206 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.194 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.159 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.155 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.153 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.152 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.151 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.149 | Idelalisib | — uncovered |